Experts in Polymer Therapeutics

Simba has a wealth of biotech and pharma experience in building companies and transformative platforms as well as developing products, having served in key executive roles at Maxygen, Systemix, Boehringer Mannheim and Celltech over his thirty-year career.  He has served as a partner and advisor at Flagship Pioneering where he was the founding CEO of Evelo Biosciences and as a Venture Partner at TPG where he was Founder CEO of Moksh8 Pharmaceuticals. Simba is currently a board member at Foghorn Therapeutics (NASDAQ – FHTX) and Sensorium Therapeutics. He earned his MBA at INSEAD and received his Ph.D. from King’s College, London.

Steve has served as interim CEO since March 2024 and CFO from March 2022 to March 2024. He has more than 35 years of experience as an investor, board member, advisor, and in operational roles with early-stage companies. He is a General Partner of Form & Fiction Ventures (FFV), a venture studio that launches and invests in startup and seed stage companies focused on socially responsible initiatives. He has served in investment management roles at Caldwell Sutter Capital, Tamalpais Partners, SF Sentry Securities, Kayne Anderson, and Fidelity Investments. Mr. Ledger received a B.A. in Economics from the University of Connecticut.

Milton served as Chair of the Serina Board of Directors since co-founding Serina in 2006. Prior to founding Serina, he was the Founder and Chief Executive Officer of Shearwater Polymers, Inc. (Shearwater). Shearwater was founded by Dr. Harris in 1992 and sold in 2001 to Nektar Therapeutics, Inc. Shearwater successfully patented, manufactured, and partnered PEG technology that enabled multiple drug products including Neulasta® (Amgen) and Pegasys® (Roche). Dr. Harris earned a B.S. from McGill University, where he also was awarded an honorary Sc.D., and a Ph.D. from the Massachusetts Institute of Technology.

Greg is the Executive Chairman of Juvenescence which he co-founded in 2017. He is also a board director of public companies Biohaven Pharmaceuticals (NYSE – BHVN) and Portage Biotech (NASDAQ – PRTG). Dr. Bailey founded and served as a director of a number of private and public companies and previously served as a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings. Dr. Bailey practiced emergency medicine for ten years before entering finance. Dr. Bailey received his M.D. from the University of Western Ontario.

Richard is the CEO of Juvenescence. He was SVP and Global Head of Respiratory & Immunology Development at AstraZeneca, overseeing the development and approval of five new medicines including the SARS CoV-2 vaccine, Vaxzevria®, and combination antibody, EvushieldTM. Prior to AstraZeneca, Richard served 16 years in increasingly senior roles at GSK, including Vice President of Fibrosis R&D. He received a Bachelor of Science in Neuroscience, a Bachelor of Medicine, a Bachelor of Surgery, and a Doctor of Philosophy in Medical Sciences from University College London. Dr. Marshall has co-authored more than 60 original publications in journals including The Lancet and The New England Journal of Medicine.

Remy has served as Vice President, Business Development & Technology Advancement at the Buck Institute for Research on Aging since 2006. Mr. Gross has advised and helped create multiple new biopharmaceutical startups at Buck, including Unity Biotechnology, Aeovian Therapeutics, and BhB Therapeutics. Prior to Buck, Mr. Gross held increasingly senior roles, including VP of Operations at Shearwater Polymers, and at Nektar Therapeutics after its acquisition of Shearwater. Mr. Gross serves as a board director of BhB Therapeutics, Napa Therapeutics, and Selah Therapeutics. Mr. Gross received a B.S. in Chemistry from Loyola University New Orleans.

Steven served on the AgeX Therapeutics board of directors from January 2024 through March 2024. . Mr. Mintz is currently President of St. Germain Capital Corp., a private consulting and investment firm. He is a principal and Chief Financial Officer of the Minkids Group, a family investment and development company. He has been a self-employed financial consultant since 1998 serving both private individuals as well as public companies in a variety of industries including real estate and investment strategies. He is currently a director of Portage Biotech. Mr. Mintz graduated from the University of Toronto.